New Framework Categorizes Closed-loop Diabetes Systems
A new standard for type 1 diabetes technology helps categorize device performance based on how well they keep blood sugar stable.
Updated on Oct. 27, 2026 in Diabetes
Live Poll
Do you trust that new diabetes technology will improve your daily quality of life?
Researchers have introduced a new consensus framework to classify fully closed-loop insulin delivery systems for type 1 diabetes. This standardization aims to provide a clearer benchmark for evaluating how effectively these automated systems manage blood glucose levels.
Why it matters
Using a measurement called time in tight range (TITR) rather than traditional time in range metrics helps researchers and clinicians focus on glucose stability that more closely correlates with a reduction in microvascular complications.
The new consensus framework establishes performance tiers based on time in tight range (70 to 140 mg/dL), requiring systems to keep time below 54 mg/dL at less than 1% of total measurement time. While the framework is defined, it remains unknown how widely these classes will be used to guide future patient device selection.
The details
The framework classifies automated insulin systems into four categories based on their ability to maintain glucose within a 70 to 140 mg/dL range. Class 1a systems must further pass a standardized 30-minute moderate exercise test, which requires two hours of fasting before the test and no glucose dips below 54 mg/dL during the activity. The criteria also require that all systems prove their efficacy through standardized patient-reported outcomes regarding quality of life and diabetes distress.
Timeline
The consensus framework was published on October 27, 2026.
Health Landscape
This framework shifts the clinical focus from general glucose management to the more precise objective of time in tight range. It serves as a necessary evolution as sophisticated technologies, such as neural network-driven delivery systems, currently undergo phase 3 clinical trials.
This framework helps standardize how effectively new insulin technology performs, which may eventually provide more clarity when choosing a device with your endocrinologist. It is worth discussing with your doctor how your current time in range data compares to these tighter stability metrics.
The takeaway
The new framework prioritizes tight glycemic control to better protect against long-term complications. Patients should continue to track their standard time in range and discuss any specific glucose stability concerns with their healthcare provider.
Further reading
For more information on the latest advancements in glucose management technology, visit Diabetes.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you trust that new diabetes technology will improve your daily quality of life?
